Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | FABP4 | P15090 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17101694 | 0.85 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1FABP4CYP1A2CYP2C19 | |
| SCHEMBL16651567 | 0.85 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1L3MBTL1FABP4CYP1A2 | |
| SCHEMBL17101815 | 0.84 | LMNA (0.43) | SMN1; SMN2L3MBTL1FABP4NSD2LMNA | |
| SCHEMBL17101687 | 0.84 | MEP1B (0.56) | SMN1; SMN2ALDH1A1FABP4CYP1A2CYP2C19 | |
| SCHEMBL17101706 | 0.84 | POLB (0.54) | SMN1; SMN2ALDH1A1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL5166003 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1L3MBTL1FABP4CYP1A2 | |
| SCHEMBL17101701 | 0.82 | NR3C2 (0.48) | SMN1; SMN2ALDH1A1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL17101772 | 0.80 | LMNA (0.52) | ALDH1A1L3MBTL1LMNACA12CA9 | |
| SCHEMBL17101682 | 0.80 | LMNA (0.51) | L3MBTL1NSD2LMNACA12CA9 | |
| SCHEMBL5892016 | 0.79 | CYP19A1 (0.57) | SMN1; SMN2ALDH1A1L3MBTL1FABP4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015140566-A1 | PYRAZOLO-PYRIMIDINES AS INHIBITORS OF BTK | REDX PHARMA PLC (GB) | 2015-09-24 | — | — | WO | disclosed |
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | SMN1; SMN2 3478/4885ALDH1A1 3296/4885L3MBTL1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.